Projected 2018 sales:
$1.516 billion
2012 sales: $1.520 billion

Kogenate's newest iteration was welcomed with open arms by hemophilia patients when it hit the U.S. market in October 2008. Approved to reduce the frequency of bleeding episodes and the risk of joint damage in patients up to age 16 with severe hemophilia A, Kogenate FS Antihemophilic Factor was the first of its kind and marked a milestone in patient care, especially that of young children.

At the time, Bayer was in the process of beefing up its specialty pharmaceutical business and, in particular, its hemophilia offerings, grabbing up Maxygen's hemophilia drug-development program in July of that year.

These days, Bayer HealthCare, which encompasses Kogenate and pulls in about half the revenue for its parent Bayer, is working to grow its prescription drug business, and it did so successfully last year with growth of 8%. CEO Marijn Dekkers has pledged to grow Bayer HealthCare by 6% per year over the next several years, and blockbuster Kogenate will surely be playing a part.

For more:
Bayer gets Kogenate approval


Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.